Wedgewood Pharmacy today announced the availability of a GS-441524 formula, a compounded oral antiviral formulation now part of its feline infectious peritonitis (FIP) treatment capabilities. With this addition, veterinarians can now prescribe both GS-441524 and Molnupiravir for their patients, two of the most requested compounded antivirals for FIP, through a single trusted source backed by pharmacist support and FDA-registered ingredient sourcing.
GS-441524 can be compounded as a 50mg/ml flavored oral oil suspension in multiple sizes, to improve compliance and ease of administration. The addition complements Wedgewood’s Molnupiravir formulations, giving veterinarians access to two antivirals with distinct mechanisms of action.
“FIP is one of the toughest diagnoses we face, not just clinically, but emotionally too,” said Dr. Rae Hutchins, Chief Veterinary Officer at Wedgewood. “For a long time, vets had to deal with inconsistent access and quality when it came to GS-441524. Now, by offering both GS-441524 and Molnupiravir from one trusted, pharmacist-supported source, we’re making it easier for veterinarians to focus on what matters most, giving their patients the best possible chance.”
"Having access to both GS-441524 and Molnupiravir compounded formulations through Wedgewood not only widens access to affordable FIP treatment across the US, but it also gives veterinarians the ability to easily choose and adapt treatment to best suit the needs of their patients and clients,” said Nicole Jacque, co-founder of FIP Global Cats. “Having pharmacists who understand the urgency and complexity of these cases partnering with veterinarians is key to ensuring the best treatment outcomes for cats with FIP.”
Until recently, many veterinarians relied on fragmented or unregulated sources for GS-441524, making it difficult to ensure consistency and continuity of care. The introduction of this option through Wedgewood reflects a direct response to those challenges, providing prescribers with a trusted, quality-assured formulation from a pharmacy they can count on.
The launch of GS-441524 builds on Wedgewood’s long-standing role in supporting veterinarians with customized treatment solutions for complex cases. As part of its commitment to responsible compounding, the pharmacy emphasizes that its GS-441524 formulation is not approved by the FDA, has not been studied in clinical trials, and Wedgewood makes no claims of efficacy or safety. Independent third-party studies related to GS-441524 are available for veterinary reference through Wedgewood’s FIP Resource Center.
To learn more about GS-441524 and access educational resources, visit www.Wedgewood.com/FIP.
About Wedgewood
Wedgewood is the nation’s largest and most trusted provider of compounded veterinary medications. Its next-generation home delivery platform, Blue Rabbit, streamlines patient care and marks a significant evolution in online pharmacy services. Together, Blue Rabbit and Wedgewood serve more than 70,000 veterinary professionals and more than one million animals annually. For more information visit www.Wedgewood.com.
About FIP Global Cats
FIP Global CATS® (Community, Advocacy, Treatment, Support) is a leading organization in the fight against feline infectious peritonitis (FIP). Uniting veterinarians, researchers, and pet owners, it provides crucial support to those facing an FIP diagnosis. The organization is committed to empowering pet parents, advocating for safe, effective and affordable legal treatments, and advancing FIP research. For more information, please visit https://www.fipglobalcats.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250605659867/en/
"Having access to both GS-441524 and Molnupiravir compounded formulations through Wedgewood not only widens access to affordable FIP treatment across the US, but it also gives veterinarians the ability to easily choose and adapt treatment."
Contacts
Jennifer Ravalli
jennifer.ravalli@wedgewood.com